Double-Class Refractory CLL in Community Practice: Current and Future Management

Personalizing First-Line Therapy for CLL

From Pixels to Practice: Advancing HCM Care With Multimodality Imaging

Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC

Double-Class Refractory CLL in Community Practice: Current and Future Management

Evidence at a Glance: The Totality of Evidence Impacting Clinical Decision-Making in Patients with HFrEF Without a Recent Worsening Event

Safety, Clinical Integration, and the Emerging Fifth Pillar in HF Practice

Navigating Treatment Sequencing After Frontline Treatment Failure in CLL

Progress in Breast Cancer Care: Translating SABCS Data Into Practice

From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma

When GDMT Isn’t Enough: Understanding Residual Risk in Patients with HFrEF

GDMT Is Working Fine, so Why Add More Therapies for Patients With HFrEF?

A Case of Missed Diagnosis, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease

Patient at High Risk of Loss to Follow-Up, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease

Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 

Do Not Delay: Timing, Triggers, and Identifying the Right Patient for Additional Therapies in HFrEF

Overcoming Cultural and Communication Disconnects, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease